By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Selexys Pharmaceuticals Corporation 

800 Research Parkway
Suite 338
Oklahoma City  Oklahoma  73104  U.S.A.
Phone: 405-319-8195 Fax: 405-319-8197



Company News
Novartis AG (NVS)' $665 Million Bet Pays Off as Selexys Shows Off New Phase II Data 12/5/2016 5:37:33 AM
Novartis AG (NVS) Scoops Up U.S. Sickle Cell Drugmaker Selexys in $665 Million Deal 11/21/2016 5:34:52 AM
Cytovance Biologics Inc. And Selexys Pharmaceuticals Corporation Announce Development And cGMP Manufacturing Agreement For SELK2 Drug Product 5/6/2014 9:34:50 AM
Selexys Pharmaceuticals Corporation Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients With Pain Crises 8/19/2013 11:06:43 AM
Cytovance Biologics Inc. Announces Manufacturing Agreement With Selexys Pharmaceuticals Corporation for Phase II Production of SelG1 11/14/2012 11:17:02 AM
Selexys Pharmaceuticals Corporation Completes $23 Million Equity Financing and Signs Agreement With Novartis Pharmaceuticals Corporation (NVS) for Up to $665 Million 9/19/2012 7:29:31 AM
Selexys Pharmaceuticals Corporation Completes Phase I Clinical Study for Sickle Cell Drug 12/19/2011 10:51:47 AM
Selexys Pharmaceuticals Corporation Initiates Enrollment in Phase I Clinical Study of SelG1 5/4/2011 10:41:28 AM
Cytovance Biologics Awarded Biopharmaceutical Development and Manufacturing Contract by Selexys Pharmaceuticals Corporation 4/26/2010 10:04:38 AM
Selexys Pharmaceuticals Corporation and Cytovance Biologics Sign Deal for the Process Development and cGMP Manufacture of Selexys Pharmaceutical Corporation’s Product HPL1 Monoclonal Antibody (Mab) 1/26/2009 9:57:57 AM